<DOC>
	<DOCNO>NCT00761540</DOCNO>
	<brief_summary>This trial conduct Asia . The aim clinical trial investigate blood concentration liraglutide ( pharmacokinetics ) well effect glucose insulin ( pharmacodynamics ) 21 day daily subcutaneous injection ( injected skin ) liraglutide placebo . In addition , safety tolerability liraglutide observe .</brief_summary>
	<brief_title>To Investigate Blood Concentration Liraglutide Well Effects Glucose Insulin After 21 Days Daily Subcutaneous Injections Liraglutide Placebo</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trial related activity Healthy Chinese male subject Body mass index ( BMI ) 19.0 27.0 kg/m2 ( inclusive ) Fasting plasma glucose le 6.0 mmol/L Nonsmoker Clinically significant abnormality prestudy clinical examination laboratory measurement screen ( abnormality discuss clinical monitor ) Presence diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder Blood pressure supine position screening , rest 5 min , outside range 90 140 mmHg systolic and/or 40 90 mmHg diastolic Pulse supine position screening , rest 5 min , outside range 40 100 times/min Hepatitis B surface antigen , Hepatitis C antibodies HIV antibody positive .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>